NASDAQ:MLTX MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis $38.40 -3.50 (-8.35%) As of 09:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MLTX alerts:Sign Up Key Stats Today's Range$38.66▼$41.5350-Day Range$32.83▼$42.3252-Week Range$31.42▼$58.26Volume346,528 shsAverage Volume350,905 shsMarket Capitalization$2.46 billionP/E RatioN/ADividend YieldN/APrice Target$80.50Consensus RatingBuy Company OverviewMoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Read More… MoonLake Immunotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreMLTX MarketRank™: MoonLake Immunotherapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 756th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMoonLake Immunotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMoonLake Immunotherapeutics has only been the subject of 4 research reports in the past 90 days.Read more about MoonLake Immunotherapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($1.79) to ($2.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MoonLake Immunotherapeutics is -30.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MoonLake Immunotherapeutics is -30.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoonLake Immunotherapeutics has a P/B Ratio of 4.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.52% of the float of MoonLake Immunotherapeutics has been sold short.Short Interest Ratio / Days to CoverMoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.Change versus previous monthShort interest in MoonLake Immunotherapeutics has recently increased by 4.41%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMoonLake Immunotherapeutics does not currently pay a dividend.Dividend GrowthMoonLake Immunotherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.52% of the float of MoonLake Immunotherapeutics has been sold short.Short Interest Ratio / Days to CoverMoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.Change versus previous monthShort interest in MoonLake Immunotherapeutics has recently increased by 4.41%, indicating that investor sentiment is decreasing. News and Social Media3.3 / 5News Sentiment0.98 News SentimentMoonLake Immunotherapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for MoonLake Immunotherapeutics this week, compared to 4 articles on an average week.Search Interest1 people have searched for MLTX on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MoonLake Immunotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.02% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MoonLake Immunotherapeutics' insider trading history. Receive MLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MLTX Stock News HeadlinesBTIG Boosts Price Target for MoonLake Immunotherapeutics (MLTX) to $85 | MLTX Stock NewsApril 30, 2025 | gurufocus.comMoonLake Immunotherapeutics: Promising Developments and Financial Strength Justify Buy RatingApril 29, 2025 | tipranks.comThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 7, 2025 | Timothy Sykes (Ad)MoonLake Immunotherapeutics: Promising Clinical Trials and Market Potential Drive Buy RatingApril 29, 2025 | tipranks.comMoonLake Immunotherapeutics: Promising Developments and Strategic Positioning Justify Buy RatingApril 29, 2025 | tipranks.comMoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29April 26, 2025 | finanznachrichten.deMoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 | MLTX Stock NewsApril 25, 2025 | gurufocus.comMoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29April 25, 2025 | gurufocus.comSee More Headlines MLTX Stock Analysis - Frequently Asked Questions How have MLTX shares performed this year? MoonLake Immunotherapeutics' stock was trading at $54.15 at the start of the year. Since then, MLTX stock has decreased by 29.1% and is now trading at $38.40. View the best growth stocks for 2025 here. How were MoonLake Immunotherapeutics' earnings last quarter? MoonLake Immunotherapeutics (NASDAQ:MLTX) issued its quarterly earnings results on Wednesday, February, 26th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.09. Who are MoonLake Immunotherapeutics' major shareholders? Top institutional investors of MoonLake Immunotherapeutics include Victory Capital Management Inc. (0.40%), Rice Hall James & Associates LLC (0.21%), Harbor Capital Advisors Inc. (0.16%) and Moody Aldrich Partners LLC (0.09%). Insiders that own company stock include Bihua Chen, Da Silva Jorge Santos, Matthias Bodenstedt, Simon Sturge and Kristian Reich. View institutional ownership trends. How do I buy shares of MoonLake Immunotherapeutics? Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MoonLake Immunotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that MoonLake Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Disc Medicine (IRON), e.l.f. Beauty (ELF), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Arista Networks (ANET). Company Calendar Last Earnings2/26/2025Today5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MLTX CIK1821586 Webwww.moonlaketx.com Phone41-41-510-8022FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$80.50 High Stock Price Target$104.00 Low Stock Price Target$66.00 Potential Upside/Downside+105.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-15.54% Return on Assets-15.09% Debt Debt-to-Equity RatioN/A Current Ratio25.51 Quick Ratio25.51 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.15 per share Price / Book4.82Miscellaneous Outstanding Shares64,012,000Free Float56,224,000Market Cap$2.51 billion OptionableOptionable Beta1.31 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:MLTX) was last updated on 5/7/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.